Loading
A phase 1/2 trial of Cisplatin in non-small-cell lung cancer, run by Wuhan YZY Biopharma Co., Ltd., now recruiting.
A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC is a phase 1/2 interventional study registered as NCT05543330 by Wuhan YZY Biopharma Co., Ltd., with 116 participants planned, started 2022-09-30 and due to reach its primary completion in 2026-09-15. Interventions recorded: M701 pleural infusion, Pleural drainage and Cisplatin pleural infusion.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy and the tag pipeline.
Shares Platinum agents, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Shares Platinum agents, Cisplatin, Cytotoxic chemotherapy, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/